154 related articles for article (PubMed ID: 35003888)
1. Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases:
Kobayashi M; Igarashi S; Takahashi T; Fujiwara S; Chida K; Terasaki K; Kubo Y; Ogasawara K
Am J Nucl Med Mol Imaging; 2021; 11(6):507-518. PubMed ID: 35003888
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical reduction of cerebral blood flow after acetazolamide loading: a hemodynamic and metabolic study with (15)O PET.
Watabe T; Shimosegawa E; Kato H; Isohashi K; Ishibashi M; Tatsumi M; Kitagawa K; Fujinaka T; Yoshimine T; Hatazawa J
Neurosci Bull; 2014 Oct; 30(5):845-56. PubMed ID: 25096497
[TBL] [Abstract][Full Text] [Related]
3. Reduced blood flow response to acetazolamide reflects pre-existing vasodilation and decreased oxygen metabolism in major cerebral arterial occlusive disease.
Yamauchi H; Okazawa H; Kishibe Y; Sugimoto K; Takahashi M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1349-56. PubMed ID: 12271418
[TBL] [Abstract][Full Text] [Related]
4. Relationship between cerebral circulatory reserve and oxygen extraction fraction in patients with major cerebral artery occlusive disease: a positron emission tomography study.
Yata K; Suzuki A; Hatazawa J; Shimosegawa E; Nagata K; Sato M; Moroi J
Stroke; 2006 Feb; 37(2):534-6. PubMed ID: 16410481
[TBL] [Abstract][Full Text] [Related]
5. PET evaluation of cerebral hemodynamics in occlusive cerebrovascular disease pre- and postsurgery.
Kuwabara Y; Ichiya Y; Sasaki M; Yoshida T; Fukumura T; Masuda K; Fujii K; Fukui M
J Nucl Med; 1998 May; 39(5):760-5. PubMed ID: 9591570
[TBL] [Abstract][Full Text] [Related]
6. Differences in Hemodynamic Alteration between Atherosclerotic Occlusive Lesions and Moyamoya Disease: A Quantitative
Igarashi C; Okazawa H; Islam MM; Tsujikawa T; Higashino T; Isozaki M; Kikuta KI
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679518
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of cerebrovascular reserve in acetazolamide challenge -comparison with acetazolamide challenge H2O-PET and Gas-PET.
Imaizumi M; Kitagawa K; Oku N; Hashikawa K; Takasawa M; Yoshikawa T; Osaki Y; Matsushita K; Matsumoto M; Hori M; Hatazawa J
Ann Nucl Med; 2004 Jul; 18(5):369-74. PubMed ID: 15462398
[TBL] [Abstract][Full Text] [Related]
8. Relationship between vasodilatation and cerebral blood flow increase in impaired hemodynamics: a PET study with the acetazolamide test in cerebrovascular disease.
Okazawa H; Yamauchi H; Toyoda H; Sugimoto K; Fujibayashi Y; Yonekura Y
J Nucl Med; 2003 Dec; 44(12):1875-83. PubMed ID: 14660711
[TBL] [Abstract][Full Text] [Related]
9. Acetazolamide-Loaded Dynamic 7T MR Quantitative Susceptibility Mapping in Major Cerebral Artery Steno-Occlusive Disease: Comparison with PET.
Fujimoto K; Uwano I; Sasaki M; Oshida S; Tsutsui S; Yanagihara W; Fujiwara S; Kobayashi M; Kubo Y; Yoshida K; Terasaki K; Ogasawara K
AJNR Am J Neuroradiol; 2020 May; 41(5):785-791. PubMed ID: 32299799
[TBL] [Abstract][Full Text] [Related]
10. Can the detection of misery perfusion in chronic cerebrovascular disease be based on reductions in baseline CBF and vasoreactivity?
Okazawa H; Tsuchida T; Kobayashi M; Arai Y; Pagani M; Isozaki M; Yonekura Y
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):121-9. PubMed ID: 16896662
[TBL] [Abstract][Full Text] [Related]
11. Neuronal activation induced BOLD and CBF responses upon acetazolamide administration in patients with steno-occlusive artery disease.
Siero JC; Hartkamp NS; Donahue MJ; Harteveld AA; Compter A; Petersen ET; Hendrikse J
Neuroimage; 2015 Jan; 105():276-85. PubMed ID: 25261002
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of central benzodiazepine receptor binding potential/cerebral blood flow SPECT imaging for detecting misery perfusion in patients with unilateral major cerebral artery occlusive diseases: comparison with cerebrovascular reactivity to acetazolamide and cerebral blood flow SPECT imaging.
Kuroda H; Ogasawara K; Suzuki T; Chida K; Aso K; Kobayashi M; Yoshida K; Terasaki K; Fujiwara S; Kubo Y; Ogawa A
Clin Nucl Med; 2012 Mar; 37(3):235-40. PubMed ID: 22310248
[TBL] [Abstract][Full Text] [Related]
13. Constant-infusion H(2)15O PET and acetazolamide challenge in the assessment of cerebral perfusion status.
Weber B; Westera G; Treyer V; Burger C; Khan N; Buck A
J Nucl Med; 2004 Aug; 45(8):1344-50. PubMed ID: 15299060
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of time dependency of the acetazolamide effect on cerebral hemodynamics as measured by 99mTc-ECD single-photon emission computed tomography].
Takaki A; Mizuta Y; Murakami M; Yonehara T; Urata J; Okada K; Takaki R; Hirano T; Fujioka S
Kaku Igaku; 2001 Jan; 38(1):31-8. PubMed ID: 11257761
[TBL] [Abstract][Full Text] [Related]
15. Pre- and Post-Angioplasty Perfusion CT with Acetazolamide Challenge in Patients with Unilateral Cerebrovascular Stenotic Disease.
You SH; Jo SM; Kim YJ; Lee JH; Jo KD; Park WS
J Korean Neurosurg Soc; 2013 Oct; 54(4):280-8. PubMed ID: 24294450
[TBL] [Abstract][Full Text] [Related]
16. Variable Temporal Cerebral Blood Flow Response to Acetazolamide in Moyamoya Patients Measured Using Arterial Spin Labeling.
Fahlström M; Wikström J; Borota L; Enblad P; Lewén A
Front Neurol; 2021; 12():615017. PubMed ID: 34168605
[TBL] [Abstract][Full Text] [Related]
17. Cerebral blood flow and oxygen metabolism measurements using positron emission tomography on the first day after carotid artery stenting.
Kawai N; Hatakeyama T; Okauchi M; Kawanishi M; Shindo A; Kudomi N; Yamamoto Y; Nishiyama Y; Tamiya T
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e55-64. PubMed ID: 24119366
[TBL] [Abstract][Full Text] [Related]
18. Capillary transit time heterogeneity inhibits cerebral oxygen metabolism in patients with reduced cerebrovascular reserve capacity from steno-occlusive disease.
Vestergaard MB; Iversen HK; Simonsen SA; Lindberg U; Cramer SP; Andersen UB; Larsson HB
J Cereb Blood Flow Metab; 2023 Mar; 43(3):460-475. PubMed ID: 36369740
[TBL] [Abstract][Full Text] [Related]
19. Cerebral MR oximetry during acetazolamide augmentation: Beyond cerebrovascular reactivity in hemodynamic failure.
Leatherday C; Dehkharghani S; Nahab F; Allen JW; Wu J; Hu R; Qiu D
J Magn Reson Imaging; 2019 Jul; 50(1):175-182. PubMed ID: 30390367
[TBL] [Abstract][Full Text] [Related]
20. Differences in vasodilatory capacity and changes in cerebral blood flow induced by acetazolamide in patients with cerebrovascular disease.
Okazawa H; Yamauchi H; Sugimoto K; Takahashi M
J Nucl Med; 2003 Sep; 44(9):1371-8. PubMed ID: 12960179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
